Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06832410 · ClinicalTrials.gov registry record · Phase 3
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
A Phase 3 study of Type 1 Diabetes and Kidney Transplant, sponsored by Vertex Pharmaceuticals Incorporated.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 10
- Enrollment target
- 7
- Study locations
NCT06832410 is a Phase 3 study of Type 1 Diabetes and Kidney Transplant that is actively recruiting participants, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 10 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (99% lower). The trial reports 7 study locations across 3 states.
The verdict
NCT06832410, a Phase 3 study of Type 1 Diabetes and Kidney Transplant, is actively recruiting participants, sponsored by Vertex Pharmaceuticals Incorporated.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 10 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.
Conditions Studied
Interventions
- BIOLOGICAL Biological/Vaccine
Study Locations (7)
Other
- Toronto General Hospital - Endocrinology - Toronto
- Vancouver General Hospital - Gordon and Leslie Diamond Health Care Centre - Vancouver
- King Abdullah International Medical Research Center (KAIMRC) - Riyadh - Endocrinology - Riyadh
- King Faisal Specialist Hospital & Research Centre - Riyadh - Endocrinology - Riyadh
Pennsylvania
- Perelman Center for Advanced Medicine - Endocrinology - Philadelphia
- Montefiore Clinical and Translational Research Center - Endocrinology - Pittsburgh
Wisconsin
- UW University Hospital - Endocrinology - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-03-31 |
| Est. Completion | 2027-09-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06832410
The ClinicalTrials.gov registry entry for NCT06832410 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (99% lower). The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Biological/Vaccine is the first listed.
NCT06832410 reports 7 study locations spanning 3 distinct geographic areas - top geographies include Other, Pennsylvania, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06832410 about?
NCT06832410 is a clinical study titled "An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant". This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.
What is the current status of trial NCT06832410?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 10 participants. The study started on 2025-03-31. Estimated completion is 2027-09-17.
What conditions does trial NCT06832410 study?
This clinical trial studies the following conditions: Type 1 Diabetes, Kidney Transplant.
What interventions are being tested in trial NCT06832410?
The interventions under investigation include: Biological/Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT06832410?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06832410 being conducted?
This trial has 7 study locations across Pennsylvania, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Single Center Study of Islet Transplantation in Non-uremic Diabetic Patients
ACTIVE NOT RECRUITING · Phase 3
-
Liraglutide in Adolescents With Type 1 Diabetes
COMPLETED · Phase 3
-
Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes
COMPLETED · Phase 3
-
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.